Several drugs with big commercial potential launched in the past year, even though many of the new entrants were for niche, rare diseases. The year 2019 was an exciting one for novel drugs, despite the fact that the number of new molecular entities approved by the US Food and Drug Administration was less than in 2018, a banner year.
Some Notable Launches In 2019
-
Two new drugs for sickle cell disease, an area that has seen a dearth of innovation, Novartis' Adakveo (crizanlizumab) and Global Blood Therapeutics' Oxbryta (voxelotor)
The US FDA approved 53 novel drugs and biologics in 2019 as of 30 December, many of which were drugs...
